FilingSEC EDGAR8-K
Citius Oncology Announces Positive Quality of Life Data for LYMPHIR from Study 302
· SEC accepted
StageClinical results announcement
Filing content
Citius Oncology announced exploratory results from Study 302 showing sustained quality of life improvements in patients with cutaneous T-cell lymphoma treated with LYMPHIR.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…